Home
Conditions
Anemia, Refractory, with Excess of Blasts

Clinical trial condition

Anemia, Refractory, with Excess of Blasts

Explore clinical trials studying Anemia, Refractory, with Excess of Blasts. Study availability and eligibility vary by location and protocol.

244 public trials 36 recruiting studies

Refine in advanced search Browse all conditions

Anemia, Refractory, with Excess of Blasts trial results

Completed

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842

Conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Anemia, +66 more
Locations: Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota, United States

Fred Hutchinson Cancer Research Center Seattle, Washington, United States

View Trial Details

Completed

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00068523

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +68 more
Locations: Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +75 more
Locations: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

NCT01866839

Conditions: ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, Anemia, +29 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

NCT01241500

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +17 more
Locations: Virginia G. Piper Cancer Center Scottsdale, Arizona, United States

University of California San Diego Moores Cancer Center La Jolla, California, United States

Stanford Cancer Center Stanford, California, United States

Yale Cancer Center New Haven, Connecticut, United States

View all 87 locations

View Trial Details

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +17 more
Locations: Stanford University Cancer Center Stanford, California, United States

Rush University Medical Center Chicago, Illinois, United States

University of Chicago Medicine Chicago, Illinois, United States

University of Kansas Cancer Center and Medical Pavilion Westwood, Kansas, United States

View all 35 locations

View Trial Details

Completed

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

NCT00923364

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +12 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

NCT00053989

Conditions: Anemia, Anemia, Aplastic, Anemia, Hypoplastic, Congenital, +67 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Completed

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813

Conditions: Anemia, Anemia, Hemolytic, Anemia, Refractory, +40 more
Locations: LDS Hospital Salt Lake City, Utah, United States

Veterans Administration Center-Seattle Seattle, Washington, United States

Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

NCT01300572

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +27 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Anemia, Refractory, with Excess of Blasts

Anemia, Refractory, with Excess of Blasts trial results

Related conditions